Introducing Fluad influenza vaccine with MF59® Adjuvant

Fluad® is a new adjuvanted seasonal influenza vaccine for adults 65 years and older.1

Adding an adjuvant to the influenza vaccine enhances the immune response to the antigens in the vaccine, which:2,3

  • increases the magnitude of the immune response by stimulating more immune cells to create more antibodies1-4*
  • broadens the immune response by creating higher levels of cross-reactive antibodies.1-4*

Fluad is distributed by Seqirus, a world leader in the development of influenza vaccines and the supplier of the funded seasonal vaccine in New Zealand.

 

*compared to non-adjuvanted, standard dose influenza vaccines 

Reference: 1. Seqirus NZ. FLUAD Data Sheet. Seqirus (NZ) Ltd. January 2020. 2. Di Pasquale A, Preiss S, Tavares Da Silva F, Garcon N. Vaccine adjuvants: from 1920 to 2015 and beyond. Vaccines (Basel). 2015;3(2):320-343. 3. Garçon N, Leroux-Roels G, Cheng WF. Vaccine adjuvants. Understanding Modern Vaccines: Perspectives in Vaccinology. 2011;1(1):89-113. 4. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine. 2001;19(17-19):2673-2680.